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Abstract
Aims: Arterial plaque rupture and thrombus characterise ST-elevation myocardial infarction (STEMI) and 
may aggravate delayed arterial healing following durable polymer drug-eluting stent (DP-DES) implantation. 
Biodegradable polymer (BP) may improve biocompatibility. We compared long-term outcomes in STEMI 
patients receiving BP-DES vs. durable polymer sirolimus-eluting stents (DP-SES).
Methods and results: We pooled individual patient-level data from three randomised clinical trials (ISAR-
TEST-3, ISAR-TEST-4 and LEADERS) comparing outcomes from BP-DES with DP-SES at four years. The 
primary endpoint (MACE) comprised cardiac death, MI, or target lesion revascularisation (TLR). Secondary 
endpoints were TLR, cardiac death or MI, and definite or probable stent thrombosis. Of 497 patients with 
STEMI, 291 received BP-DES and 206 DP-SES. At four years, MACE was significantly reduced following 
treatment with BP-DES (hazard ratio [HR] 0.59, 95% CI: 0.39-0.90; p=0.01) driven by reduced TLR (HR 
0.54, 95% CI: 0.30-0.98; p=0.04). Trends towards reduction were seen for cardiac death or MI (HR 0.63, 
95% CI: 0.37-1.05; p=0.07) and definite or probable stent thrombosis (3.6% vs. 7.1%; HR 0.49, 95% CI: 
0.22-1.11; p=0.09).
Conclusions: In STEMI, BP-DES demonstrated superior clinical outcomes to DP-SES at four years. Trends 
towards reduced cardiac death or myocardial infarction and reduced stent thrombosis require corroboration 
in specifically powered trials.
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Introduction
Biodegradable polymer-based drug-eluting stents (BP-DES) provide 
controlled drug release followed by degradation of the polymer coat-
ing, eventually rendering the stent surface similar to that of a bare 
metal stent (BMS). This design has been hypothesised to reduce the 
incidence of late adverse events, which have been linked to durable 
polymer coatings in some patients1,2. Studies of BP-DES have dem-
onstrated safety and long-term efficacy versus durable polymer DES 
in a broadly inclusive patient population, with a reduction in very late 
definite stent thrombosis seen up to four years2.
Patients with ST-segment elevation myocardial infarction 
(STEMI) have poorer outcomes after percutaneous coronary 
intervention (PCI) compared to those with stable coronary artery 
disease, with higher rates of stent thrombosis and increased risk 
of reinfarction persisting at long-term follow-up3,4. Although PCI 
with DES improves efficacy outcomes in patients with STEMI, 
maintenance of superior safety outcomes in the long term has not 
yet been conclusively demonstrated in comparison to BMS in 
STEMI, even for newer-generation DES5-8. Late adverse events 
have been linked to an inflammatory reaction and delayed arterial 
healing – at least in part due to durable polymer coatings – and 
the extent of this problem may be more pronounced in the setting 
of STEMI.
Consequently, the definition of the optimal DES device in 
STEMI remains unresolved and the search for ideal DES therapy 
for this condition continues. In this pooled analysis we aimed to 
evaluate long-term performance of BP-DES in comparison to dura-
ble polymer DES in a high-risk subset of patients with STEMI.
Methods
PATIENT POPULATION AND DEVICE DESCRIPTION
We performed a patient-level pooled analysis of the three larg-
est multicentre, randomised clinical trials comparing biodegrada-
ble polymer DES with a leading first-generation durable polymer 
sirolimus-eluting stent (SES) for coronary revascularisation (the 
ISAR-TEST-3 trial [ClinicalTrials.gov identifier: NCT00350454]9, 
the ISAR-TEST-4 trial [ClinicalTrials.gov identifier: NCT00598676]10 
and the LEADERS trial [ClinicalTrials.gov identifier: 
NCT00389220]11) and analysed outcomes in the subset of patients 
with STEMI. From an overall population of 4,062 patients in the 
original trials, a total of 497 patients with STEMI were included in 
the present analysis: 291 of these were randomly allocated to treat-
ment with biodegradable polymer DES (either Yukon PC Choice, 
backbone produced by Translumina, Hechingen, Germany, or 
BioMatrix Flex; Biosensors Inc., Newport Beach, CA, USA), and 
206 were allocated to treatment with durable polymer SES (Cypher 
Select; Cordis, Miami Lakes, FL, USA). The Yukon PC Choice 
stent comprised a pre-mounted, sandblasted microporous 316L 
stainless steel stent coated with sirolimus and a polylactate poly-
mer which fully degraded within nine weeks; the BioMatrix Flex 
stent is a stainless steel stent with an abluminal coating of bioli-
mus and a polylactate polymer degrading fully within six months. 
Detailed descriptions of the design of the three trials are reported in 
the primary publications9-11. A summary of the principal trial charac-
teristics was reported previously12. Patients were followed up clini-
cally up to four years after enrolment by the investigating sites.
PROCEDURAL AND DISCHARGE MEDICATION
In all three trials, an oral loading dose of 300-600 mg clopidogrel 
was administered before or at the time of the PCI procedure. During 
the procedure, all patients received unfractionated heparin or biva-
lirudin. The use of glycoprotein IIb/IIIa antagonists was left at the 
discretion of the operators. On discharge, all patients were pre-
scribed aspirin at least 75 mg daily indefinitely and clopidogrel 
75 mg daily for at least 12 months.
ENDPOINTS AND DEFINITIONS
The pre-specified primary endpoint was the occurrence of major 
adverse cardiac events (MACE), defined as the composite of car-
diac death, myocardial infarction (MI), and target lesion revascular-
isation (TLR). Secondary endpoints were TLR (efficacy endpoint), 
the composite of MI or cardiac death and definite or probable stent 
thrombosis (safety endpoint). Cardiac death was defined as death 
due to immediate cardiac causes or complications related to the pro-
cedure, as well as any death in which a cardiac cause could not be 
excluded. Definitions of MI were consistent across the pooled tri-
als; however, in the ISAR-TEST-4 trial (and in patients included 
from ISAR-TEST-3) target-vessel MI was adjudicated, whereas 
in the LEADERS trial any MI was included. TLR was defined 
as any clinically indicated repeat revascularisation (percutaneous 
or surgical) of the target lesion. The definition of clinically indi-
cated revascularisation was consistent across the included trials. 
Stent thrombosis was defined according to the Academic Research 
Consortium criteria in all studies13.
TRIAL QUALITY ASSESSMENT
All trials were assessed for bias using components recommended by 
the Cochrane Collaboration, including: sequence generation of the 
allocation; allocation concealment; blinding of participants, person-
nel, and outcome assessors; selective outcome reporting; and other 
sources of bias14. Trials with high or unclear risk for bias for any one 
of the first three components were considered as having high risk 
of bias. Otherwise, they were considered as having low risk of bias.
STATISTICAL ANALYSIS
Categorical data are presented as counts and proportions (%). 
Continuous data are presented as mean (±SD) or median [25th-
75th percentiles]. Individual patient data were pooled and analysed 
according to intention to treat. Survival analysis was performed 
using the Mantel-Cox method stratified by the trial. Fulfilment of 
the proportional hazards assumption was checked before each anal-
ysis. Trials in which the event of interest was not observed in either 
treatment group were omitted from the analysis of that event. In 
the event that only one of the treatment groups from a trial had 
no event of interest, then the estimated treatment effect estimate 
and its standard error were calculated after adding 0.5 to each 
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Long-term outcomes of biodegradable polymer DES in STEMI
cell of the 2×2 table for that trial15. Cochrane tests were used 
to assess heterogeneity across trials. Consistency between tri-
als was measured by calculating the I2 statistic - with values of 
25, 50, and 75% indicating low, moderate, and high inconsistency, 
respectively16. Results were considered statistically significant at 
two-sided p<0.05. Statistical analysis was performed using the 
Stata software package, version 9.2 (StataCorp, College Station, 
TX, USA). Survival curves are presented as simple, non-stratified 
Kaplan-Meier curves and were constructed with the use of S-Plus 
software version 4.5 (Insightful Corporation, Seattle, WA, USA).
Results
From a total of 4,062 enrolled patients in the original trials, 2,358 
received BP-DES and 1,704 DP-SES. In total, 497 patients with 
STEMI were included in the present analysis, of whom 291 
received BP-DES and 206 received durable polymer SES. A sum-
mary of included trials is shown in Table 1.
Patient characteristics were broadly similar; however, those 
receiving biodegradable polymer DES had a lower prevalence of 
hypercholesterolaemia, a greater prevalence of multivessel disease 
at baseline and a lower percentage diameter stenosis immediately 
post intervention (Table 2). Clinical outcomes up to four years as 
well as landmark analyses are summarised in Table 3. There was 
no heterogeneity across trials and no interaction between treatment 
effect of BP-DES and trial origin for any of the endpoints analysed. 
At four years, the incidence of MACE was significantly reduced 
with BP-DES versus durable polymer SES (14.2% vs. 23%; HR 
0.59, 95% CI: 0.39-0.90; p=0.01) (Figure 1). This was driven by 
a reduction in target lesion revascularisation (7.4% vs. 13.1%; HR 
0.54, 95% CI: 0.30-0.98; p=0.04) (Figure 2) and a trend for reduc-
tion in cardiac death or MI (9.5% vs. 15.0%; HR 0.63, 95% CI: 0.37-
1.05; p=0.07) (Figure 3). Stent thrombosis was numerically lower 
Table 2. Baseline characteristics.
Biodegradable 
polymer stent 
(N=291)
Durable 
polymer SES 
(N=206)
p-value
Age (years) 62.5±12.1 63.1±12.6 0.56
Male 214 (73.5%) 149 (72.3%) 0.76
Diabetes 56 (19.2%) 34 (16.5%) 0.43
Hypertension 142 (48.8%) 110 (53.4%) 0.31
Hypercholesterolaemia 119 (40.8%) 109 (52.9%) <0.01
Current smoker 120 (41.2%) 91 (44.2%) 0.51
Family history of coronary artery 
disease
91 (31.3%) 76 (36.9%) 0.19
History of MI 40 (13.7%) 21 (10.2%) 0.23
History of PCI 34 (11.7%) 29 (14.1%) 0.43
Previous CABG 11 (3.8%) 9 (4.4%) 0.74
Left ventricular ejection fraction (%) 47±10 48±12 0.46
Coronary artery disease at baseline <0.01
 1 vessel 148 (50.9%) 136 (66.0%)
 2 vessel 73 (25.1%) 36 (17.5%)
 3 vessel 70 (24.1%) 30 (16.5%)
Target vessel 0.69
Bypass graft 1 (0.3%) 2 (1.0%)
Left main stem 2 (0.7%) 1 (0.5%)
Left anterior descending 131 (45.0%) 86 (41.8%)
 Right coronary artery 54 (18.6%) 34 (16.5%)
 Left circumflex 103 (35.4%) 83 (40.3%)
Lesion length - mm 16.2±9.1 14.5±7.4 0.16
Reference vessel diameter - mm 2.8±0.6 2.8±0.5 0.61
Stenosis pre-intervention (%) 80.3±19.1 80.8±20.9 0.24
Stenosis post-intervention (%) 8.4±10.6 13.3±16.0 <0.01
Balloon diameter - mm 3.1±0.5 3.1±0.4 0.64
Stented length - mm 25.9±12.6 27.7±14.2 0.25
Data are mean±SD or number (%). CABG: coronary artery bypass grafting; MI: myocardial 
infarction; PCI: percutaneous coronary interventionTable 1. Summary of included trials.
ISAR-TEST-3 ISAR-TEST-4 LEADERS
Number of patients 605 2,603 1,707
Stent type BP-SES
DP-SES
PF-SES
BP-SES
DP-SES
DP-EES
BP-BES
DP-SES
Number of STEMI patients 
included in this analysis
2 220 275
Primary endpoint Late lumen loss Composite of death,
target vessel MI or
clinically driven TLR
Composite of 
cardiac death,
MI or clinically 
driven TVR
Inclusion criteria Symptoms or evidence
of ischaemia
Symptoms or evidence
of ischaemia
No restriction
Clinical exclusion criteria Acute MI
Cardiogenic shock
Cardiogenic shock None
Lesion exclusion criteria In-stent restenosis
Left main stem lesions
Bypass graft lesions
In-stent restenosis
Left main stem lesions
Bypass graft lesions
None
BP: biodegradable polymer; DP: durable polymer; BES: biolimus-eluting stent; EES: 
everolimus-eluting stent; MI: myocardial infarction; PF: polymer-free; SES: sirolimus-eluting 
stent; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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Figure 1. Kaplan-Meier curves for cardiac death, myocardial 
infarction or target lesion revascularisation for the pooled 
population in each of the treatment groups. CI: confidence interval; 
HR: hazard ratio
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in those receiving BP-DES; however, this did not reach statistical 
significance for definite stent thrombosis (2.5% vs. 5.5%; HR 0.44, 
95% CI: 0.17-1.14; p=0.08) or definite or probable stent thrombo-
sis (3.6% vs. 7.1%; HR 0.49, 95% CI: 0.22-1.11; p=0.09) (Figure 4).
Table 3. Clinical outcomes up to 4 years, overall and according to 
a landmark analysis at 1 year.
Biodegradable 
polymer stent 
(N=291)
Durable 
polymer SES 
(N=206)
Hazard ratio 
(95% CI)
p-value
Cardiac death, MI 
or TLR*
40/291 (14.2) 46/206 (23.0) 0.59 (0.39-0.90) 0.01
0 to 1 year 27/291 (9.4) 32/206 (15.8) 0.58 (0.35-0.96) 0.03
1 to 4 years 13/255 (5.2) 14/169 (8.6) 0.62 (0.29-1.31) 0.21
Cardiac death or MI 27/291 (9.5) 30/206 (15.0) 0.63 (0.37-1.05) 0.07
0 to 1 year 20/291 (7.0) 19/206 (9.3) 0.74 (0.39-1.38) 0.34
1 to 4 years 7/262 (2.7) 11/182 (6.3) 0.44 (0.17-1.14) 0.09
Cardiac death 20/291 (7.1) 21/206 (10.5) 0.67 (0.36-1.24) 0.20
0 to 1 year 14/291 (4.9) 14/206 (6.9) 0.71 (0.34-1.48) 0.36
1 to 4 years 6/268 (2.3) 7/187 (3.9) 0.60 (0.20-1.80) 0.37
Death 31/291 (10.9) 27/206 (13.4) 0.81 (0.48-1.36) 0.43
0 to 1 year 21/291 (7.3) 16/206 (7.9) 0.93 (0.48-1.78) 0.82
1 to 4 years 10/268 (4.0) 11/187 (6.0) 0.64 (0.27-1.51) 0.31
MI 9/291 (3.3) 12/206 (6.2) 0.52 (0.22-1.24) 0.14
0 to 1 year 7/291 (2.5) 8/206 (4.0) 0.61 (0.22-1.69) 0.34
1 to 4 years 2/262 (0.8) 4/182 (2.4) 0.34 (0.06-1.86) 0.21
TLR 20/291 (7.4) 25/206 (13.1) 0.54 (0.30-0.98) 0.04
0 to 1 year 12/291 (4.4) 19/206 (9.7) 0.43 (0.21-0.89) 0.02
1 to 4 years 8/256 (3.2) 6/170 (3.8) 0.89 (0.31-2.56) 0.83
Definite or probable 
stent thrombosis
10/291 (3.6) 14/206 (7.1) 0.49 (0.22-1.11) 0.09
0 to 1 year 8/291 (2.9) 13/206 (6.5) 0.43 (0.18-1.03) 0.06
1 to 4 years 2/262 (0.8) 1/178 (0.6) 1.35 (0.12-14.84) 0.81
Definite stent 
thrombosis
7/291 (2.5) 11/206 (5.5) 0.44 (0.17-1.14) 0.08
0 to 1 year 6/291 (2.1) 11/206 (5.5) 0.38 (0.14-1.03) 0.06
1 to 4 years 1/267 (0.4) 0/182 (0.0) – 0.89
Percentages (%) are Kaplan-Meier estimates. *Primary endpoint. CI: confidence interval; 
MI: myocardial infarction; TLR: target lesion revascularisation
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Figure 3. Kaplan-Meier curves for cardiac death or myocardial 
infarction for the pooled population in each of the treatment groups. 
CI: confidence interval; HR: hazard ratio
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Figure 2. Kaplan-Meier curves for target lesion revascularisation for 
the pooled population in each of the treatment groups. 
CI: confidence interval; HR: hazard ratio
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Figure 4. Kaplan-Meier curves for definite or probable stent 
thrombosis for the pooled population in each of the treatment groups. 
CI: confidence interval; HR: hazard ratio
Discussion
In the present study, we analysed individual patient data from three 
randomised trials comparing biodegradable polymer DES with 
the leading first-generation durable polymer SES in 497 patients 
with STEMI up to four years. The main finding was that treatment 
with biodegradable polymer DES significantly improved clini-
cal outcomes. All components of MACE favoured the BP-DES: 
TLR demonstrated a significant reduction and cardiac death or MI 
showed a trend towards reduction. Although stent thrombosis was 
numerically lower following BP-DES, the reduction seen in this 
group did not achieve statistical significance.
DES achieve greater antirestenotic efficacy in comparison with 
bare metal stents at the cost of delayed healing of the treated arte-
rial segment17-19. Pathological studies have shown evidence of 
a persistent inflammatory response in the arterial wall, and durable 
polymer coatings have been heavily implicated in the aetiology of 
this response in some patients18,19. Delayed arterial healing follow-
ing DES is a pathophysiological process characterised by persistent 
fibrin deposition, inflammatory cell infiltration, ongoing platelet 
activation and delayed endothelial regrowth and has been associ-
ated with adverse vessel remodelling, stent thrombosis and ongoing 
late restenosis17-19.
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Long-term outcomes of biodegradable polymer DES in STEMI
Numerous reports have highlighted STEMI as a risk factor for 
late reinfarction and late stent thrombosis following primary inter-
vention3,4,20. This is thought to be due to a combination of factors 
including adverse lesion morphology and high thrombus burden, 
persistent inflammation and increased platelet reactivity, as well 
as chronic processes associated with delayed healing and vessel 
remodelling21. Additionally, intravascular imaging following DES 
implantation in STEMI has shown that at follow-up a higher pro-
portion of struts remains uncovered compared to BMS22-24 and that 
incomplete DES apposition25,26 is observed more frequently, a find-
ing that appears to indicate adverse vessel remodelling and confer 
a higher risk of subsequent stent thrombosis.
Given this background, BP-DES may represent an attractive 
solution for patients with STEMI, as complete polymer biodeg-
radation after drug elution is expected to result in a vessel wall-
stent interaction resembling that seen after bare metal stenting. 
Intravascular imaging studies have shown encouraging data regard-
ing vessel healing following biodegradable polymer DES implan-
tation in man27,28. Moreover, in a broadly inclusive patient cohort, 
BP-DES demonstrated a reduction in clinically indicated target 
lesion revascularisation and very late definite stent thrombosis up 
to four years in comparison to durable polymer SES12, an effect 
potentially magnified in patients with STEMI.
Our study represents the first analysis of long-term outcomes 
in patients with STEMI treated with BP-DES and the first spe-
cific comparison of BP-DES and durable polymer DES in STEMI. 
There are several significant findings. First, although biodegradable 
polymer DES have been hypothesised to offer improved outcomes 
mainly in the long term, differences in stent thrombosis are evident 
early, and analysis shows a significant difference in MACE and TLR 
already evident at one year and persisting up to four years. Although 
the reduction in MACE of 42% seen at one year in comparison to 
durable polymer SES was similar to the margin demonstrated by 
a biodegradable polymer biolimus-eluting stent in comparison to 
a BMS seen in the recent COMFORTABLE AMI trial (4.3% vs. 
8.7%; p<0.01)29, this does not help to explain the onset of the differ-
ence or to define the role of biodegradable polymer in this regard. 
Although polymer may fully biodegrade in as little as nine weeks, 
it is difficult to attribute all of the observed effects to biodegradable 
polymer in isolation, and other factors may play a role.
Second, rates of stent thrombosis were numerically lower in 
those treated with biodegradable polymer DES, although this nar-
rowly failed to reach statistical significance at one or four years, 
a finding similar to that demonstrated in the STEMI subgroup of 
the COMFORTABLE AMI trial at one year29.
Third, the reduction seen regarding MACE in patients with 
STEMI treated with BP-DES was driven by a reduction in TLR 
and a trend for reduced death or MI. In actual fact, the absolute 
magnitude of the treatment effects was greater than that seen in the 
overall study cohort12. This suggests that new-generation BP-DES 
with enhanced biocompatibility may have particular benefit in the 
high-risk subgroup of patients who present with STEMI and who 
undergo primary percutaneous coronary intervention.
STUDY LIMITATIONS
The present study has several limitations. First, although the three 
source studies were all randomised, they were not specifically 
designed for STEMI patients and did not perform stratified randomi-
sation according to the presence of STEMI. As a post hoc analysis, 
the results should be considered hypothesis-generating.
Second, the present study comprises a large-scale compari-
son of biodegradable polymer versus durable polymer DES in 
patients with STEMI; however, the sample size remains inad-
equate to determine statistical significance of differences in 
incidence of rare clinical outcomes between the two treatment 
groups.
Third, even though inclusion criteria were broad across all 
three included trials, there remained slight differences in the char-
acteristics of patients enrolled in the individual trials. Despite 
this, our analysis showed no evidence of any heterogeneity across 
the trials. Fourth, the comparator SES was the leading stent of its 
generation at the time when the studies were conducted. Thus, 
the comparative efficacy results cannot be extrapolated to cur-
rent DES platforms using other limus family drugs and different 
polymers.
Finally, the study not only compared biodegradable and durable 
polymers but also three separate stent platforms with differences 
which may in part explain the observed outcomes. Although the 
lack of interaction between BP-DES treatment effect and trial ori-
gin suggests clinical homogeneity and both biodegradable polymer 
stents contain polylactic acid monomer coatings and elute limus-
agent drugs, differences in polymer degradation, drug efficacy and 
stent backbone mean that significant differences in their relative 
performance may be expected.
Conclusion
In the current pooled analysis of patients with STEMI undergoing 
PCI, biodegradable polymer DES compared to durable polymer 
SES demonstrated improved overall clinical outcome, reduced 
need for revascularisation as well as trends towards lower inci-
dence of cardiac death or MI and reduced stent thrombosis at 
long-term follow-up. These findings support the use of biode-
gradable polymer DES in patients with STEMI but should be con-
firmed in dedicated randomised controlled trials against leading 
new-generation comparators.
Impact on daily practice
The choice of stent implanted in patients undergoing PCI for 
STEMI affects arterial healing and influences clinical outcomes. 
Biodegradable polymer DES provide, when used in this high-
risk setting, high clinical efficacy and good patient safety which 
remain comparable to durable polymer DES out to the long 
term. Dedicated randomised controlled trials with long-term 
follow-up trials are required to investigate the observed trend 
towards a reduction in stent thrombosis and cardiac death or MI 
with biodegradable polymer DES in STEMI. 
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